This fusion protein, TβRI-TβRII-Fc chimeric receptor, could counteract TGF-β-induced mesenchymal properties in malignant melanoma cells in vitro and reduce B16 melanoma tumor growth in vivo. The gene discussed is TGFBR1; the disease is neoplasm.